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Abstract
The intracellular functions of myosin motors requires a number of
adaptor molecules, which control cargo attachment, but also fine-
tune motor activity in time and space. These motor–adaptor–cargo
interactions are often weak, transient or highly regulated. To
overcome these problems, we use a proximity labelling-based
proteomics strategy to map the interactome of the unique minus
end-directed actin motor MYO6. Detailed biochemical and func-
tional analysis identified several distinct MYO6-adaptor modules
including two complexes containing RhoGEFs: the LIFT (LARG-
Induced F-actin for Tethering) complex that controls endosome
positioning and motility through RHO-driven actin polymerisation;
and the DISP (DOCK7-Induced Septin disPlacement) complex, a
novel regulator of the septin cytoskeleton. These complexes
emphasise the role of MYO6 in coordinating endosome dynamics
and cytoskeletal architecture. This study provides the first in vivo
interactome of a myosin motor protein and highlights the power
of this approach in uncovering dynamic and functionally diverse
myosin motor complexes.
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Introduction
In eukaryotic cells, myosin motor proteins regulate the distribution
of a wide variety of cytoplasmic cargo by mediating short-range
transport or tethering of organelles, vesicles, mRNA and protein
complexes. The myosin superfamily can be grouped into at least 35
different classes, which all translocate towards the plus-end of actin
filaments with the exception of MYO6 [1]. The unique directionality
of MYO6 facilitates its specific cellular roles in endocytosis, receptor
trafficking, protein secretion and autophagy. Loss of these functions
underlies a number of phenotypes observed in the MYO6-null Snell’s
waltzer mouse, or in humans harbouring mutations in the MYO6
gene, including deafness, astrogliosis, proteinuria as well as hyper-
trophic cardiomyopathy [2–6]. Furthermore, overexpression of
MYO6 is a hallmark of a number of cancers including prostate
cancer [7].
The functional and phenotypic diversity associated with MYO6
arises from interactions with multiple cargo adaptors including
disabled-2 (DAB2), GAIP-interacting protein C-terminus (GIPC1),
target of Myb 1 (TOM1), lemur tyrosine kinase 2 (LMTK2), opti-
neurin (OPTN), TAX1 binding protein 1 (TAX1BP1) and nuclear dot
protein 52 (NDP52) [8–13]. These interactions occur at two major
protein binding motifs, the RRL and WWY (named after their amino
acid composition), which are located within two distinct sub-
domains of a unique C-terminal cargo-binding tail [10,11]. The tail
also contains a phosphatidylinositol 4,5-bisphosphate (PIP2) binding
motif, which aids recruitment of the motor to membranes along with
its binding partners [14]. In addition, two distinct ubiquitin-binding
sites—a motif interacting with ubiquitin (MIU) and a MYO6 ubiqui-
tin-binding domain (MyUb)—in the tail region may bind ubiquiti-
nated cargo or regulate other interactions [15,16]. These adaptor
interactions mediate targeting of the motor to its appropriate cellular
location, making them a critical determinant of motor function.
Interestingly, adaptor binding to the tail domain not only medi-
ates cargo attachment but can also coordinate motor activity. In the
case of MYO6, cargo binding can initiate unfolding, thereby releas-
ing inhibition of motor activity [17]. In addition, growing evidence
suggests that the myosin tail region can also directly impact on actin
filament dynamics: for example, myosins of class IX contain a tail
domain with RhoGAP activity [18]; MYO5A interacts with the actin
nucleator SPIRE2 to coordinate actin polymerisation on RAB11
endosomes [19]; and myosins of class I can interact with machinery
that regulates the ARP2/3 complex, and thus actin remodelling,
during endocytosis in both yeast and mammalian cells [20–22].
Together, these findings highlight an emerging role for the myosin
tail domain beyond simple cargo recognition, in modulating both
motor activity and the actin track.
Traditional approaches such as yeast two-hybrid, native
immunoprecipitation as well as pull-down assays with the
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cargo-binding tail domain have thus far mainly uncovered only
direct MYO6 cargo adaptors, but not organelle anchors or cargoes
themselves, which might often comprise multi-protein complexes.
New approaches are thus required to identify weak, transient
motor–cargo and motor–track interactions, which enable the
spatial and temporal coordination of diverse MYO6 functions.
Therefore, to uncover the larger MYO6 interaction network—the
MYO6 interactome—we employed in situ proximity labelling by
BioID to identify proteins that may enable the spatial and temporal
regulation of cargo binding to MYO6 as well as its motor activity
and actin track dynamics [23]. This method utilises a promiscuous
variant of the E. coli biotin ligase (BirA*) which releases a reactive
biotin intermediate (biotinoyl-50-AMP) into its surroundings
[23,24]. Subsequently, biotinoyl-50-AMP can react with primary
amines in proximal proteins which can then be isolated using the
high-affinity interaction between the newly generated biotin tag
and streptavidin. As the biotin is covalently attached to its target,
this permits lysis and purification under harsh, denaturing condi-
tions while still preserving weak or transient interactions.
This first in vivo proximity map of a myosin motor protein high-
lights the complex interactome and multi-functionality of MYO6 and
includes a new direct binding partner and at least four new multi-
protein complexes. We verified a large number of these network
components by affinity pull-down and functional analysis, thereby
highlighting a potential role for MYO6 in coordinating actin dynam-
ics with endosome function and septin filament positioning. This
approach provides a powerful means of elucidating the dynamic
subcomplexes formed by unconventional myosins to orchestrate
diverse roles and coordinate motor activity with cytoskeletal dynam-
ics.
Results
The MYO6 interactome reveals numerous novel binding partners
To capture its dynamic, highly transient cargo interactions, we used
in situ proximity labelling (BioID) to survey the MYO6 interactome
in living cells under steady state conditions. We generated retinal
pigment epithelial (RPE) cell lines stably expressing BirA*-MYO6
fusion proteins of the cargo-binding domain (CBD) derived from the
“no insert” isoform (NI), which is targeted predominantly to early
APPL1-positive endosomes; or the “large insert” isoform (LI), which
is targeted strongly to clathrin-coated structures (CCS) positive for
DAB2 (Fig 1A–C). As BioID has a limited labelling radius, we used
the truncated CBD in our experiments which is sufficient for adaptor
and lipid binding and therefore subcellular targeting.
We performed large-scale streptavidin pull-downs from BirA*,
BirA*-MYO6 CBD NI and BirA*-MYO6 CBD LI RPE cell lines and
identified enriched proteins by mass spectrometry (MS). BirA*-
MYO6 CBD replicates were analysed by MS and compared against a
bank of 10 BirA* only negative control experiments using the online
tool at CRAPome.org [25]. Using a fold-change (FC-A) threshold of
≥ 3 and a Significance Analysis of INTeractome (SAINT) probability
threshold of ≥ 0.8 [26], we identified 102 high-confidence proximal
proteins. These included the majority of the known direct binding
partners of MYO6 such as TOM1/L2, DAB2, GIPC1 and LMTK2, in
addition to > 90 novel MYO6-associated proteins, which might bind
directly or as part of larger MYO6-associated protein complexes
(Fig 1D). Comparison of the NI and LI showed 39 shared interac-
tions and 16 or 47 specific interactions for the LI and NI isoforms,
respectively. Many of the known direct binding partners of MYO6
appear in the shared pool of interactions for the two isoforms
(Fig 1E). This confirms our previous observations that binding of
DAB2 and other adaptors is not isoform specific [8,10,14], but
targeting of the LI isoform to clathrin-coated structures is directed
by the large insert [27]. As a result, the LI still appears to show
enrichment for CCS proteins such as AP2 subunits, SYNJ1 and
PICALM, whereas the NI specific interactions are less well anno-
tated but are likely to link it to diverse cellular localisations and
functions.
Mutational profiling identifies distinct MYO6-associated
protein complexes
To verify the novel MYO6 interaction network, we introduced
mutations into the known cargo-binding and lipid-binding sites,
the WWY, RRL and PIP2 binding motifs [10,11,14] and assessed
▸Figure 1. The MYO6 interactome reveals numerous novel binding partners.A Schematic diagram of BirA*-MYO6 CBD wild-type and mutant constructs.
B myc-BirA*-MYO6 CBD RPE cell lines were analysed by immunoblot using myc and GAPDH (loading control) antibodies.
C Immunofluorescence microscope images of RPE cells stably expressing myc-BirA*-MYO6 CBD NI (top row) and myc-BirA*-MYO6 CBD LI (bottom row) treated with
50 lM biotin for 24 h. Cells were immunostained with antibodies to myc (blue), APPL1 (green, top row), DAB2 (green, bottom row) or streptavidin (red) to visualise
biotinylated proteins. Scale bar, 20 lm.
D Diagram of all direct and indirect interactions identified for MYO6 NI and LI using BioID. Edge length corresponds to FC-A score (lower score = greater length) and
node size to SAINT score (lower confidence = smaller node). Green and blue nodes indicate interactions specific to the NI and LI isoforms, respectively, and cyan
indicates shared partners. Previously described interactions are highlighted by red outlines.
E Graph depicting relative enrichment (the fold-change ratio) of proteins in pull-downs from MYO6 NI and LI expressing cells. Dot size corresponds to SAINT score
(lower confidence = smaller dot).
F Schematic diagram of SILAC workflow.
G Plot depicting mean log2 fold change for each protein in (H) across the different MYO6 mutants. Colours correspond to those in (H).
H Table of proteins identified with a significant (significance A, FDR < 5%) loss in at least one experiment. Heavy/light ratios are provided and > twofold losses are
highlighted in colour. Proteins are grouped by colour based on pattern of loss across the different MYO6 mutants.  = not identified in the experiment.
I Plot of principal component analysis using the mean log2 fold change from triplicate experiments. The figure shows the projections of the data on the first (x-axis)
and second (y-axis) principal components. Principal components 1–3 account for 76.12, 17.6 and 6.274% of the variability in the data, respectively. CARD10 was
excluded from the analysis due to its absence from the DRRL data set. Dashed boxes highlight the clusters likely to represent distinct MYO6-associated protein
complexes. Colours correspond to those in (H).
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differences in the relative abundance of BirA*-MYO6 binding part-
ners using a SILAC-based approach (Fig 1F). Analysis of these
cells by confocal microscopy also revealed that the DRRL and
DPIP2, but not the DWWY mutation, perturbed MYO6 targeting to
APPL1 endosomes (Fig EV1A). The different tail mutants caused
loss of specific MYO6 binding partners; for example, mutation of
the known DAB2 binding site, the WWY motif, led to the loss of
DAB2 as well as other endocytosis-associated proteins such as
EPS15L1 and FCHO2 (Fig 1G and H). Alternatively, deletion of the
RRL and PIP2 motifs caused reduced association of the early endo-
some proteins APPL1 and APPL2, and the RRL with TOM1/L2.
Finally, LRCH3, LRCH1 and DOCK7 interactions were blocked by
mutation of both the WWY and RRL motifs (Fig 1G and H). Use of
principal component analysis to cluster the data according to
shared behaviour across the mutants implied the existence of four
independent MYO6-associated protein complexes containing the
known MYO6 binding partners DAB2, TOM1/L2, APPL1/2 and
DOCK7, respectively (Fig 1I).
The MYO6 interactome can be verified by secondary screens
To further explore the composition of these MYO6-associated
complexes, we performed secondary BioID screens using four high-
confidence hits from the MYO6 interactome: GIPC1, the uncharac-
terised protein LRCH3 and the guanine nucleotide-exchange factors
(GEFs) DOCK7 and LARG. These screens with secondary baits iden-
tified a MYO6 interactome containing more than 130 proteins,
summarised in the network in Fig 2. By combining our data with
interaction data from public databases and using a semi-supervised
clustering approach, we uncovered distinct clusters corresponding
to putative MYO6-associated complexes. These data largely over-
lapped with the mutational profiling experiments, identifying: a
complex containing DAB2 involved in clathrin-mediated endocyto-
sis; proteins such as GIPC1 and TOM1 associated with early endo-
somes; a multitude of proteins linking MYO6 to distinct functions at
the plasma membrane or peripheral endosomes; and an uncharac-
terised complex composed of DOCK7 and multiple members of the
Figure 2. The MYO6 interactome can be verified by secondary screens.
Diagram of the MYO6 protein interaction network identified by BioID (solid lines) with MYO6 (white), GIPC1, LARG, LRCH3 and DOCK7 (yellow) baits and supplemented
with interaction data available in public databases (dashed lines). Previously identified MYO6 binding partners are indicated in pink. Lower confidence interactions (> 3 FC-A,
< 0.8 SAINT) are indicated by red lines. All proteins < 2 interactions in the network were excluded for simplicity and further adjustments made manually. Proteins were
clustered using a force-directed layout function in Cytoscape [58]. Putative complexes/subcellular locations are highlighted by the dashed boxes.
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leucine-rich repeat and calponin homology domain-containing
(LRCH) protein family.
GIPC1 links MYO6 to multiple protein complexes
Mapping of the GIPC1 interactome using BioID identified 25 high-
confidence interaction candidates including multiple members of
the signalling and scaffold complex STRIPAK (MOB4, STRN, STRN3
and STRN4) [28] (Figs 2 and 3A). The GIPC1 and MYO6 data sets
contained 14 mutual interactions including known links such as
APPL1/2 and several novel shared associations such as GULP1,
LZTS2, FAM160A1, SIPA1L1/3 and FMNL3 (Fig 3A). Of particular
interest were LARG, SH3BP4 and CARD10, which were extremely
high-confidence MYO6 interactors, and were also present in the
GIPC1 data set to varying degrees. BirA*-LARG pull-downs revealed
five high-confidence interactions, which included both GIPC1 and
SH3BP4 (Figs 2 and 3A).
We next validated these putative MYO6-GIPC1 complexes using
complementary methodologies. Full-length SH3BP4 and domain
fragments of LARG were tested for binding by immunoprecipitation
(IP) from HEK293T cells or for direct interactions using the mamma-
lian two-hybrid (M2H) assay. These experiments confirmed the exis-
tence of a complex consisting of MYO6, GIPC1, LARG and SH3BP4
(Fig 3B). The C-terminal fragment of LARG (amino acids 1171–
1544) co-immunoprecipitated GIPC1, MYO6 and SH3BP4, and
appears to be incorporated into the complex through an interaction
with the N-terminal end of the PDZ domain of GIPC1 (Figs 3C and
EV2A). SH3BP4 also co-immunoprecipitated GIPC1 and MYO6, and
engaged the complex through the C-terminal fragment of GIPC1,
much like MYO6 (Figs 3C and EV2B). As SH3BP4 successfully co-
immunoprecipitated MYO6, it appears they can bind the C-terminal
region of GIPC1 simultaneously.
We observed that CARD10 contains a C-terminal PDZ binding
motif, SEA, which is identical to the motif present in APPL1 and is
required for its interaction with GIPC1, but not found in other CARD
proteins (CARD11 and CARD14). IPs from HEK293T cell expressing
GFP-tagged full-length CARD10 confirmed binding to GIPC1 and
MYO6; however, deletion of the SEA motif completely abolished
binding (Fig EV2C). As expected, CARD10 bound directly to full-
length GIPC1 via its C-terminal SEA motif in the M2H assay
(Fig EV2D).
Together, these data show that, in addition to its known interac-
tions with APPL1 and VANGL1 [29], GIPC1 also links MYO6 to; a
quadripartite complex containing LARG and SH3BP4; a separate
complex containing CARD10; and likely other network components
such as GULP1, FAM160A1, FMNL3 or LZTS2 that require further
analysis. This therefore highlights the remarkable multi-function-
ality of MYO6 at endosomes in conjunction with GIPC1.
The LIFT complex regulates MYO6-driven actin reorganisation
We next investigated a potential role of the MYO6-GIPC1-LARG-
SH3BP4 complex in regulating actin filament organisation, as LARG
is a GEF for RHO GTPases and SH3BP4 localised to actin structures
including filopodia at the cell surface (Fig 3D). For this analysis, we
used an engineered mutant of MYO6 (MYO6+), which moves in the
opposite direction to the wild-type protein [30]. As previously
shown, this mutant clusters early endosomes and induces actin
reorganisation, leading to the formation of filopodia protruding from
the cell surface, above a cortical cluster of endosomes, in a GIPC1-
dependent manner [30]. Indeed, in mutant MYO6+-expressing cells
GIPC1, SH3BP4 and LARG are all recruited to MYO6+-induced
filopodia (Fig 3E). Furthermore, depletion of LARG and SH3BP4
using siRNA markedly reduced the number of MYO6+ cells that
generated filopodia. By contrast, the knock-downs had no effect on
GFP-MYO10-induced filopodia formation (Figs 3F and EV2E and F).
Taken together, these results indicate a role for LARG and SH3BP4
in MYO6+-dependent actin reorganisation in the cell cortex.
LPAR1-LARG-RHO-dependent actin reorganisation controls
endosome positioning
LARG contains a regulator of G protein signalling (RGS) domain that
can directly bind to the activated subunit of heterotrimeric G
proteins such as Ga12 and 13. Interestingly, LARG has previously
been linked to signalling from GPCRs such as the lysophosphatidic
acid receptor (LPAR1), that is also trafficked by GIPC1 and MYO6
through APPL1 endosomes (Figs 4A and B, and EV3A) [31–33]. We
therefore determined whether the MYO6-GIPC1-LARG-SH3BP4
complex links LARG and RHO-dependent actin organisation to
GIPC1 endosome function and position. We analysed actin filament
distribution and APPL1-positive endosome localisation upon activa-
tion of the canonical LPAR1-LARG-RHOA signalling pathway after
treating cells with LPA for 5 min. Quantitation revealed a modest
non-significant increase in actin filaments and APPL1 signal inten-
sity as well as colocalisation of APPL1 with actin upon LPA
▸Figure 3. GIPC1 links MYO6 to multiple protein complexes.A Dot plot of high and medium confidence interactions (> 3 FC-A and > 0.8 SAINT or > 3 FC-A and < 0.8 SAINT, respectively) identified in BirA*-GIPC1 and BirA*-LARG
experiments and shared interactors from the BirA*-MYO6 CBD interactome.
B Network diagram of the LIFT complex.
C Top: Schematic cartoon of LARG domain structure. Bottom: GFP nanobody immunoprecipitates from HEK293T cells transfected with GFP and GFP-tagged LARG
fragments encompassing amino acids 1–274 (PDZ-CC), 274–721 (RGSL), 721–1172 (DH-PH) and 1171–1544 (COOH) (left) or GFP and full-length GFP-SH3BP4 (right).
Samples were analysed by Western blot with the indicated antibodies.
D Confocal microscope images of SH3BP4 HeLa siRNA KD cells immunostained for SH3BP4 (red) and actin (green). Images are maximum intensity projections of
confocal stacks. Views through the z-stack (yellow dashed line) are shown. Scale bar, 20 lm. Graphs (i) and (ii) on the right: pixel intensity profiles of SH3BP4 and
actin labelling along yellow line.
E Confocal microscope images of HeLa cells transiently transfected with GFP-MYO6+ (green) and immunostained for SH3BP4 (top row, red), LARG (bottom row, red) and
actin (blue). Images are maximum intensity projections of confocal stacks. Scale bar, 20 lm.
F Graph depicting the mean percentage of MYO6+ or MYO10-positive cells treated with mock, LARG or SH3BP4 siRNA which generated filopodia. Counts were
performed on cells from 10 fields of view (typically 10–30 cells/field) and n = 3 independent experiments. A two-sample t-test was used to determine statistical
significance. ***P < 0.001. Error bars indicate SEM.
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stimulation (Figs 4C and EV3B). Likewise, overexpression of the
unregulated LARG RhoGEF domain led to significant increases in
actin bundles, APPL1 signal intensity and APPL1 colocalisation with
actin, indicated by the dramatic alignment of APPL1-positive endo-
somes along filaments (Figs 4D and EV3C). Live cell microscopy
indicated that the APPL1 endosomes aligned along actin filaments
had greatly reduced motility (Fig EV3D and Movie EV1). Finally,
ectopic expression of constitutively active RHOA, RHOB and RHOC
also triggered an increase in actin filament bundles and subsequent
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Figure 4. LPAR1-LARG-RHO-dependent actin reorganisation controls endosome positioning.
A Schematic of the LPA-LARG-RHO signalling pathway.
B Confocal microscope images of 0 min (upper panels) or 5 min (lower panels) LPAR1 uptake in HeLa cells expressing GFP-MYO6 CBD and HA-tagged LPAR1 in the
presence of 10 lM LPA. Cells were immunostained for GFP (green), APPL1 (red) and LPAR1 (blue). Scale bar, 20 lm.
C Confocal microscope images of HeLa cells serum starved (upper panels) or treated with 10 lM LPA for 5 mins (lower panels) and immunostained for APPL1 (red) and
actin (green). Scale bar, 20 lm. Graph to the right depicts the mean Pearson’s correlation coefficient calculated for actin and APPL1 in serum starved or LPA
stimulated cells from ≥ 5 fields of view (2–6 cells/field) in n = 3 independent experiments (> 70 cells per condition). Paired t-test P = 0.097. Error bars indicate SEM.
D Confocal microscopy of HeLa cells expressing GFP-LARG GEF immunostained for APPL1 (red) and actin (green). Scale bar, 20 lm. Graph to the right depicts the mean
Pearson’s correlation coefficient calculated for actin and APPL1 in GFP or GFP-LARG GEF transfected cells from ≥ 7 fields of view (1–7 cells/field) in n = 4 independent
experiments (> 100 cells per condition). Significance was calculated using a two-sample t-test. ***P < 0.001. Error bars indicate SEM.
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Taken together, these data suggest that the LIFT complex is an
actin regulatory module, which may function downstream of GPCRs
such as LPAR1 to drive RHO-mediated actin reorganisation to regu-
late endosome positioning and motility. These results support, and
may provide the molecular mechanism for, our recent finding that
MYO6 mediates association of APPL1 endosomes with cortical actin
filaments [30,34]. Depletion of MYO6 or expression of the reverse
MYO6+ affects endosome localisation in the cell cortex. In this way,
MYO6 could either regulate endosome position directly through
organelle tethering to actin filaments or indirectly through reorgani-
sation of the actin cytoskeleton involving recruitment of RhoGEFs
such as LARG.
MYO6 is linked to the RhoGEF DOCK7 via LRCH3
Our in situ proximity labelling and mutational profiling resolved
another putative MYO6-associated protein complex composed of
DOCK7 and LRCH family proteins. DOCK7 is a GEF for RAC1 and
CDC42, which forms a complex with MYO6 to regulate neurite
outgrowth [35,36]. Secondary screens in BirA*-LRCH3 expressing
cells identified five high-confidence interactions, as well as several
lower confidence hits, including DOCK7, a number of septin family
members, protein phosphatase 6 (PP6) components as well as utro-
phin and syntrophins (Figs 2 and 5A). BirA*-DOCK7 labelling iden-
tified only three high-confidence interactions, all of which were
LRCH family proteins (LRCH1, LRCH3 and LRCH4), as well as lower
confidence interactions with other DOCK proteins (Figs 2 and 5A).
The LRCH3, DOCK7 and MYO6 data sets showed overlap with
multiple LRCH and DOCK family proteins in addition to the PP6
component ANKRD28, indicating that LRCH3, DOCK7 and LRCH1
indeed form a distinct MYO6-associated protein complex (Fig 5B).
We next confirmed the interactions between MYO6, LRCH3 and
DOCK7 and mapped the topology of the complex by performing pull-
down experiments using full-length and functional domain fragments
of LRCH3 and DOCK7. These experiments showed both MYO6 and
DOCK7 can bind to LRCH3; DOCK7 binds to its leucine-rich repeats
and MYO6 to a region between amino acids 383–648 (Fig 5C). Analy-
sis of IPs with different GFP-DOCK7 fragments indicated that both
MYO6 and LRCH3 bound to the DHR2 domain of DOCK7 (Fig 5C).
The observations that MYO6 and LRCH3 both bound to the same site
on DOCK7, but MYO6 and DOCK7 bound distinct sites on LRCH3
imply that LRCH3 is the linker between MYO6 and DOCK7. Indeed,
our M2H assay confirmed that LRCH3 interacts directly with MYO6;
the binding site again mapped to amino acids 363–648 and required
both the WWY and RRL motif in the MYO6 CBD, corroborating our
earlier SILAC experiments (Figs 1E and 5D).
Although other LRCH family members such as LRCH1 were iden-
tified in the MYO6 and DOCK7 BioID data sets, no interaction
between LRCH1 and MYO6 was observed, although LRCH1 did co-
immunoprecipitate DOCK7 (Fig EV4A and B). Indeed, LRCH family
proteins show high levels of conservation within the N-terminal
LRRs at the site of DOCK7 binding, but very little in the region of
the MYO6 binding site (Fig EV4C).
The DISP complex regulates septin organisation
Finally, our BioID experiments identified a possible interaction
between LRCH3 and a number of septins. Septins are a family of
GTPases, which oligomerise to form filaments and other higher
order structures, templated by the actin cytoskeleton [37]. At steady
state, septins localise along actin bundles in the cell body, but are
absent from more dynamic membrane ruffles (Fig EV5A). As we
were unable to observe septins in LRCH3 IPs (the same IP was posi-
tive for MYO6 and DOCK7; compare Figs 5C and EV5B), we verified
this interaction using a knock sideways approach that targeted GFP-
LRCH3 to mitochondria using a GFP binding domain fused to a
mitochondria-targeting sequence (MitoGBD). Co-expression of
MitoGBD with GFP alone, full-length GFP-LRCH3 or GFP-tagged
domain fragments of LRCH3 in RPE cells caused all to relocalise to
the mitochondria; however, only relocalisation of full-length LRCH3
or a fragment containing its calponin homology domain triggered
the concomitant recruitment, and oligomerisation, of SEPT7, from
its steady state localisation along actin filaments to mitochondria
(Figs 6A and EV5C). Interestingly, despite sharing a highly
conserved calponin homology domain with LRCH3, full-length GFP-
LRCH1, which does not interact with MYO6, failed to relocalise
septins (Figs 6A and EV5C). Overexpression of LRCH3 alone does
not lead to any obvious changes in actin filament organisation but
led to the displacement of septins from actin filaments and the
assembly of cytosolic ring-like septin structures in a small but signif-
icant population of cells (Fig 6B–D). To determine whether MYO6
and DOCK7 also localised to these septin structures, we co-
expressed HA-MYO6 CBD or GFP-DOCK7 DHR2 and found both co-
localised with myc-LRCH3 and SEPT7 (Fig 6B and C). Strikingly
however, the co-expression of LRCH3 and the DOCK7 DHR2
domain, which contains the LRCH3 and MYO6 binding sites as well
as the RAC1/CDC42 GEF activity of DOCK7, caused a very dramatic
increase in the number of cells (~80%) containing septin ring struc-
tures (Fig 6D). These data provide the first evidence for a possible
role of LRCH3 and DOCK7 in the remodelling of the septin
cytoskeleton.
Discussion
In this study, we have used proximity labelling-based proteomics to
follow the dynamic interactions of the cargo-binding tail of MYO6
in situ. To our knowledge, this is the first in vivo interaction map
identified for a myosin motor protein. Using proximity-dependent
labelling in the native cellular environment, we have successfully
identified and, by comprehensive biochemical characterisation, vali-
dated a number of novel protein complexes that link MYO6 to hith-
erto unknown functions. The MYO6 interactome contains over 100
proteins which we have grouped into several distinct functional
complexes. This large network of interactions is likely to be required
for the multitude of cellular tasks that require this reverse actin-
based motor in mammalian cells.
Most notably, we have identified two new MYO6 complexes
containing RhoGEFs, which regulate the actin cytoskeleton and
thereby receptor trafficking at early endosomes or modulation of the
septin cytoskeleton. The first is LARG, a GEF for RHO GTPases,
which is one of the 15 shared interactions between MYO6 and
GIPC1. Together with SH3BP4, these three proteins exist in a quadri-
partite complex, the LIFT (LARG-Induced F-actin for Tether-
ing) complex, which we implicate in actin modulation at
early endosomes. We show that the GEF activity of LARG or
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LPAR1-LARG-RHO signalling can affect the positioning and motility
of MYO6-GIPC1-positive endosomes. The role of MYO6 and GIPC1
in the transport of vesicles and receptors through the cortical actin
network is well established [38–40]; thus, by linking MYO6-GIPC1
to LARG, we highlight the possibility that LARG and SH3BP4 might




Figure 5. MYO6 is linked to the RhoGEF DOCK7 via LRCH3.
A Dot plot of high and medium confidence interactions (> 3 FC-A and > 0.8 SAINT or > 3 FC-A and < 0.8 SAINT) identified in BirA*-LRCH3 and BirA*-DOCK7 experiments
and shared interactors from the BirA*-MYO6 CBD interactome.
B Network diagram of the DISP complex.
C Top: Schematic cartoon highlighting domain structure, fragments and binding sites found in LRCH3 (left) and DOCK7 (right). Bottom: GFP nanobody
immunoprecipitates from HEK293T cells transfected with GFP, full-length GFP-LRCH3 and GFP-LRCH3 fragments corresponding to amino acids 1–382 (LRR), 383–648
(Unc) or 649–777 (CH) or GFP-DOCK7 fragments corresponding to amino acids 1–500 (NH2), 501–1000 (DHR1), 1001–1500 (Int) or 1501–2140 (DHR2). Samples were
analysed by Western blot with the indicated antibodies.
D The mammalian two-hybrid assay was used to test direct binding of full-length LRCH3 and wild-type, DWWY or DRRL MYO6 tail and full-length LRCH3 or LRCH3
fragments and wild-type MYO6 tail. Graph shows relative luciferase activity from a single representative experiment.
Source data are available online for this figure.
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remodelling of the actin cortex to modulate vesicle trafficking. The
perturbation in filopodia formation by engineered mutant MYO6+
upon depletion of either LARG or SH3BP4 would seem to support
this. Furthermore, as LARG is activated by the stimulation of speci-
fic GPCRs (e.g. LPAR1) which traffic through MYO6-GIPC1 endo-
somes [31–33], it is attractive to hypothesise that the interaction
between LARG and GIPC1 might serve as a feed-forward mechanism
to regulate the subsequent retrograde movement of internalised
receptors (Fig 7A). In addition, these endosomes are thought to
serve as signalling platforms. As such, this ability to modulate vesi-
cle motility is likely to mediate not only receptor traffic and degrada-
tion but also the duration of signal transduction. Indeed, we have
◀ Figure 6. The DISP complex regulates septin organisation.A Widefield microscope images of RPE cells expressing HA-MitoGBD and GFP (top row), full-length GFP-LRCH3 (middle row) or GFP-LRCH3 fragment 649–777 (CH;
bottom row). Cells were immunostained with HA (blue), GFP (green) and SEPT7 (red) antibodies. Scale bar, 20 lm. Graph to the right depicts the Pearson’s correlation
coefficient calculated for GFP and SEPT7 in RPE cells transfected with GFP, full-length GFP-LRCH3, GFP-LRCH3 fragments and GFP-LRCH1. Graph displays the mean
calculated from 10 fields of view (1 cell/field) from n = 3 independent experiments. Statistical significance was determined by repeated measures ANOVA and a
Bonferroni post hoc test. ***P < 0.001. Error bars indicate SEM. Below, schematic cartoon highlighting domain structure of LRCH3 and the putative SEPT7 binding
site.
B Structured illumination microscope images of RPE cells transiently transfected with GFP-tagged LRCH3, immunostained with GFP (green), SEPT7 (top row) or DOCK7
(bottom row, red) antibodies and labelled with phalloidin to visualise actin (blue). Scale bar, 5 lm or inset, 1 lm.
C Confocal microscope images of RPE cells stably expressing myc-LRCH3 and transiently transfected with HA-MYO6 CBD NI (upper panels) or GFP-DOCK7 DHR2 domain
(lower panels, GFP-DOCK7 GEF). Cells were immunostained with myc (blue), HA (top row, green) or GFP (bottom row, green) and SEPT7 (red) antibodies. Scale bar,
20 lm.
D Graph depicting the mean percentage of GFP-DOCK7 GEF or myc-LRCH3-positive cells which displayed septin oligomerisation. Counts were performed on > 100 cells
per condition from n = 3 independent experiments. Statistical significance was determined by two-sample t-test. ***P < 0.001. Error bars indicate SEM.
A B
Figure 7. Model of LIFT/DISP complex function.
A Upon activation of Ga12/13-coupled receptor at the cell surface (e.g. LPAR1), LARG is activated and the receptor is internalised into MYO6-GIPC1-positive endosomes.
LARG is able to catalyse the GDP-GTP exchange of RHO GTPases which can then activate their downstream effectors to promote actin remodelling. The interaction
between LARG and GIPC1 links this activity to the endosome to promote actin reorganisation in proximity to the trafficking receptor. This actin remodelling might
affect endosome position and motility.
B LRCH3 is able to displace septins (green) from actin filaments (blue) via its C-terminal calponin homology domain. Once septins are displaced from the actin, DOCK7
can promote actin remodelling via its activity towards RAC1 and CDC42 GTPases.
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recently shown a role for MYO6 and GIPC1 in regulating Akt signal-
ling on this compartment [34] and it will be interesting to further
address the role of the LIFT complex in this pathway.
The second RhoGEF, DOCK7, is a GEF for both RAC1 and
CDC42 [41] and has previously been associated with MYO6
[35,36]. Here, we show DOCK7 links via LRCH3 to MYO6 to form
the septin regulatory DISP (DOCK7-Induced Septin disPlacement)
complex. Interestingly, proximity-dependent labelling with LRCH3
identified a link to septins, important components of the cytoskele-
ton. In mammalian cells, septins can assemble into higher order
structures including rings and filaments. These filaments have
been linked to the actin cytoskeleton by colocalisation and obser-
vations that perturbation of the actin cytoskeleton causes the
formation of septin rings or, conversely, septin depletion triggers
the loss of actin [37,42,43]. Our experiments show overexpression
of the DISP complex promotes the formation of septin rings,
indicative of septin displacement from actin, demonstrating that
these proteins are a novel class of septin regulator. Interestingly,
we and others observe that septins filaments are largely excluded
from dynamic actin structures such as membrane ruffles and
appear to stabilise actin bundles [42,43]. RAC1 and CDC42 are
both potent regulators of actin dynamics and septin organisation
[43,44], and it is therefore tempting speculate that DOCK7 might
exert its effect on the septin cytoskeleton via its GEF activity
towards those GTPases (Fig 7B). Further work will be required to
determine the precise mechanistic details of this, but we propose
that the DISP complex might locally coordinate removal of the
actin stabilising septin scaffold to allow MYO6-dependent actin
remodelling driven by DOCK7.
Together, this work highlights an emerging paradigm in myosin
function, the coordination of myosin activity and actin filament
assembly. Specifically, class IX myosins have RhoGAP domains in
their tails, MYO5 has recently been shown to coordinate motor
targeting with assembly of actin tracks by binding to the actin nucle-
ator SPIRE2 [19], and myosins of class I can interact directly with
proteins that regulate actin patch formation at the plasma
membrane [20–22]. Our identification of two distinct MYO6-
associated RhoGEF complexes, which link to different actin modula-
tory pathways, builds significantly on this regulatory theme and
highlights the extent to which motor activity is synchronised with
actin track assembly. Overall our results suggest that myosin motors
do not simply translocate along pre-existing actin filaments, but can
actively induce actin tracks as required.
Advanced proteomics provides an exciting opportunity to explore
the regulation and function of transient complexes formed by motor
proteins. Although some known partners such as the autophagy
receptors NDP52, TAX1BP1 or OPTN were not identified in our
BioID experiments, this likely reflects their MYO6 interactions occur
in a tissue-specific or temporally-restricted manner. Additional
proteomics studies could be adapted to uncover such complexes.
Nonetheless, the identification of > 90 novel MYO6 interacting
proteins and two new regulatory complexes highlights the power of
this technology and provides a rich resource for the cytoskeletal
community. With advances in proteomic analyses of post-transla-
tional modifications such as phosphorylation and ubiquitination,
this approach could have further utility in determining how specific
signalling pathways regulate myosin motor activity and cargo bind-
ing in specific subcellular contexts.
Materials and Methods
Antibodies and reagents
Antibodies used in this work were as follows: myc (05-724; 1:200
IF, 1:2,000 WB) monoclonal antibody (Millipore); DAB2 (sc-13982;
1:200 IF, 1:2,000 WB), APPL1 (sc-67402; 1:100 IF, 1:1,000 WB),
SH3BP4 (sc-393730; 1:50 IF, 1:500 WB), LARG (sc-25638; 1:50 IF),
SEPT7 (sc-20620, 1:50 IF, 1:1,000 WB) and EF2 (sc-13004; 1:2,000
WB) antibodies (Santa Cruz); GIPC1 (25-6792; 1:100 IF, 1:1,000
WB) polyclonal antibody (Proteus); GAPDH (G8795; 1:10,000 WB)
monoclonal antibody (Sigma); HA (11867423001, 1:200 IF) antibody
(Roche); GFP (A11122; 1:400 IF) polyclonal antibody (Life Tech-
nologies); GFP (ab1218; 1:400 IF) monoclonal antibody (Abcam);
affinity-purified rabbit polyclonal antibodies against GFP (1:2,000
WB) and MYO6 (1:100 IF, 1:1,000 WB) were generated as described
previously [45]. Affinity-purified rabbit polyclonal antibodies
against amino acids 383–648 of LRCH3 (1:1,000 WB) or amino acids
1500–2140 of DOCK7 (1:1,000 WB) were generated as part of this
work.
Plasmids
The pcDNA3.1 myc-BirA (R118G) generated by Kyle Roux was
obtained from Addgene (35700 [23]) and subcloned into the pLXIN
retroviral vector. MYO6 CBD LI (isoform 1, Q9UM54-1, amino acids
1037–1285) and MYO6 CBD NI (isoform 5, Q9UM54-5, amino acids
1036–1253) WT, DWWY, DRRL and DPIP2 were amplified by PCR
from MYO6 FL and tail wild-type, DWWY, DRRL and DPIP2 pEGFPC
constructs described elsewhere [8,46–48] and inserted in-frame at
the 30 end of the BirA* tag. Mammalian two-hybrid MYO6 tail wild-
type and mutant pM constructs have been described elsewhere [9],
as have GFP-MYO6+ and GFP-MYO10 [30]. HA-MYO6 CBD was
generated by PCR using primers containing the HA tag sequence.
Full-length GIPC1 (isoform 1, UniProtKB O14908-1) and DOCK7
(isoform 4, Q96N67-4) were generated by PCR from RPE cDNA.
Full-length LARG, SH3BP4, LRCH3 and LRCH1 cDNA (clone IDs:
184137, 6138465, 2960711 and 40126023, respectively) were
obtained from Thermo Fisher Scientific, and CARD10 cDNA (clone
ID: 8322711) was obtained from GE Healthcare. Full-length inserts
or truncations were amplified by PCR and ligated into pEGFPC,
pVP16, pM or myc-BirA* pLXIN2 as relevant. To generate myc-
LRCH3 RPE stable cell lines, full-length LRCH3 was ligated into
pCMV-myc and subcloned into pLXIN retaining the myc tag.
GFP-CDC42 (12600) and GFP-RAC1 (13720) generated by Klaus
Hahn; GFP-RHOA Q63L (12968) by Gary Bokoch; and RHOC
pEGPFC2 (23226) and RHOD pcDNA3 (23235) by Channing Der
were all obtained from Addgene [49–52]. myc-RHOB pcDNA was a
kind gift from Philip Woodman (University of Manchester). RHOB,
RHOC and RHOD were mutated by site-directed mutagenesis to
generate the corresponding constitutively active mutants. HA-
LPAR1 was obtained from the Harvard PlasmID repository
(HsCD00000181) and subcloned into pIRES-neo2. SEPT7 (isoform 1,
Q16181-1) was generated by PCR from RPE cDNA and ligated into
pEGFPC or pIRES-neo2 retaining the GFP tag. The pOPINE GFP
nanobody (49172) plasmid generated by Brett Collins was obtained
from Addgene [53]. The HA-MitoGBD pCAG was generated by PCR
amplification of the GFP nanobody (GBD) insert and ligation into
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HA-MitoFKBP pCAG, a kind gift from Margaret Robinson (Univer-
sity of Cambridge)
Cell culture and transfections
HeLa cells were cultured in RPMI-1640, CHO cells in F12 HAM and
RPE cells in a 1:1 mixture of DMEM and F12 HAM. All medium
contained sodium bicarbonate and was supplemented with 10%
FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 lg/ml strepto-
mycin. HEK293T cells and the derivative Phoenix retrovirus
producer cell line were cultured in DMEM containing GlutaMAXTM
and supplemented with 10% FBS, 100 U/ml penicillin and
100 lg/ml streptomycin. For comparative proteomics experiments,
cell populations were labelled with heavy or light amino acids. RPE
cells were cultured through three passages in SILAC DMEM:F12
(1:1) medium (Thermo Fisher Scientific) supplemented with 10%
dialysed FBS (Gibco) and 147.5 mg/l L-arginine 13C6
15N4 (Arg10;
Cambridge Isotope Laboratories) and 91.25 mg/l L-Lysine 13C6
15N2
(Lys8; Cambridge Isotope Laboratories) heavy amino acids or their
light equivalents.
DNA transfections were performed using FuGENE6 transfection
reagent (Promega) according to the manufacturer’s instructions for
both RPE and HeLa cells, or using PEI (Polysciences) for HEK293T
cells. For RNAi-mediated gene silencing siRNA ON-TARGETplus
SMARTpool oligonucleotides (Dharmacon, GE Healthcare) targeting
LARG and SH3BP4 were transfected into cells using Oligo-
fectamineTM (Invitrogen) according to the manufacturer’s instruc-
tions. To ensure optimal knock-down, all cells were transfected on
day 1 and again on day 3, seeded according to application on day 4
and assayed on day 5.
For BioID experiments, cells were treated with complete medium
supplemented 50 lM biotin (Sigma) for 24 h. For LPA stimulation
experiments, HeLa cells were starved overnight in serum-free RPMI
and stimulated with 10 lM LPA (Sigma) for the indicated time.
Generation of stable cell lines
RPE cell lines stably overexpressing myc-BirA* fusion proteins or
myc-LRCH3 were generated by retroviral transduction. Virus was
generated by transfecting the Phoenix retroviral producer line with
the pLXIN retroviral packaging vector. After 48 h, virus was
harvested and used to infect parental RPE cells before selection with
500 lg/ml G418 (Gibco). RPE cells stably expressing GFP-SEPT7
were generated by stable transfection and selection in G418. GFP-
positive populations were subsequently enriched by fluorescence-
activated cell sorting.
Immunofluorescence microscopy
Cells were grown on sterilised coverslips, fixed in 4% formalde-
hyde, permeabilised with 0.2% Triton X-100 and blocked with 1%
BSA in PBS before incubation with the relevant primary antibody
and, subsequently, with AlexaFluor488/568/647-conjugated
secondary antibodies (Molecular probes). DNA was visualised with
Hoechst, biotin with AlexaFluor568-conjugated streptavidin
(Molecular probes) and actin with AlexaFluor488/568/647-conju-
gated phalloidin (Molecular probes). For structured illumination
microscopy experiments, cells were grown on acid-washed, No. 1.5,
18 mm square coverslips (high performance 170  5 lm, Schott,
Germany). For antibody uptake experiments, cells were starved
overnight, incubated for 15 min at 4°C with HA antibody before
uptake at 37°C in the presence of 10 lM LPA for the indicated time.
Images were obtained using a 63× objective on a Zeiss LSM710
confocal microscope, a Zeiss AxioImager upright widefield epifluo-
rescence microscope equipped with an ORCA Flash 4 v2 camera or,
for SIM, on a Zeiss Elyra PS1 super-resolution microscope. To
measure colocalisation, images were taken from randomly selected
fields of view, background subtracted and cells manually segmented
using ImageJ. The Pearson’s correlation coefficient was then calcu-
lated using the ImageJ plugin coloc2. Statistical analysis was
performed in GraphPad Prism as indicated.
Mammalian two-hybrid assay
To map direct interactions, bait and prey were amplified by PCR
and ligated into the pVP16 or pM vectors (Clontech). Mammalian
two-hybrid experiments were performed in CHO cells as described
previously [54].
Nanobody purification and Affi-Gel conjugation
GBD pOPINE was expressed in C41 E. coli cells and purified as
described in [14,45]. GFP nanobody was coupled to Affi-Gel 10 resin
(Bio-Rad) as per the manufacturer’s instructions.
Western blotting and immunoprecipitation
Cells lysates were prepared in 1% NP-40 buffer (50 mM Tris–HCl at
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and complete
protease inhibitor cocktail [Roche]) on ice, separated by SDS–PAGE
and transferred to Immobilon-FL polyvinylidene difluoride (PVDF)
membrane (Millipore) by wet transfer. Membranes were blocked in
5% milk, incubated overnight at 4°C with primary antibodies
diluted in 5% milk and HRP-conjugated secondary antibodies
(a-rabbit/mouse/goat IgG-HRP, Sigma) in 5% milk for 1 h at room
temperature; 5% BSA was used to block streptavidin-HRP blots.
Membranes were developed using enhanced chemiluminescence
(ECL) substrate (GE Healthcare) and exposure to Super RX-N medi-
cal X-ray film (Fuji).
Immunoprecipitations were performed with HEK293T cells grow-
ing on 100-mm dishes. 24 h post-transfection cells were lysed with
1% NP-40 lysis buffer, homogenised using a 25G needle and clari-
fied by centrifugation at 20,000 × g for 15 min at 4°C. Lysates were
precleared with TBS-blocked Affi-Gel resin before incubating for 3 h
with a 10 ll bead bed of GFP-nanobody Affi-gel resin. After washing
with lysis buffer three times and TBS twice, proteins were eluted
using SDS sample loading buffer and boiling before analysis by
immunoblot.
BioID purification and sample processing
For large-scale MS BioID experiments, cells were seeded onto 2×
150-mm dishes. At 50% confluency, cells were fed with fresh
complete growth medium supplemented with 50 lM biotin and
incubated for 24 h to allow labelling. Biotinylated cells were lysed
with RIPA lysis buffer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl,
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1% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS and
complete protease inhibitor cocktail), homogenised using a 25G
needle and, after sonification, clarified by centrifugation. Clarified
lysates were mixed with high capacity streptavidin beads (Thermo
Scientific, #20357) for 3 h at 4°C. Beads were washed with RIPA
buffer three times, TBS twice and ammonium bicarbonate pH 8
(ABC, Sigma) before incubation for 30 min at 56°C in 10 mM DTT
(Sigma, BioXtra). The solution was spiked with 10 ll 550 mM
Iodoacetamide (IAA, Sigma, BioUltra) incubated for 20 min and
washed before digestion overnight in 50 mM ABC containing 0.5 lg
of Trypsin Gold (Promega). An additional 0.5 lg of trypsin was
added the following day and incubated for a further 2 h at 37°C.
The supernatant was collected, and beads were washed twice with
150 ll of HPLC-grade H2O (Sigma, CHROMASOLV
) and all super-
natants combined. The pooled eluant was spiked with 1 ll of 100%
trifluoroacetic acid (TFA) and dried to a pellet in a vacuum centri-
fuge. For SILAC BioID experiments, heavy and light amino acid-
labelled cells were each seeded onto individual 150-mm dishes.
Lysates were quantified using the Precision Red Advanced Protein
Assay Kit (Cytoskeleton) as per the manufacturer’s instructions and
equal amounts of protein pooled before processing in the same way.
MS acquisition and data analysis
Samples were resuspended in MS solvent (3% acetonitrile, 0.1%
TFA) for analysis on a Q Exactive (Thermo Scientific) coupled to an
RSLC3000nano UPLC (Thermo Scientific). Peptides were resolved
using a 50 cm C18 PepMap EASYspray column with a gradient
rising from 97% solvent A (0.1% formic acid), 3% solvent B (80%
acetonitrile, 0.1% formic acid) to 40% solvent B over 40 min. Data
were acquired in a top 10 data-dependent acquisition fashion with
MS spectra acquired between m/z 400 and 1,400 at 70,000 fwhm.
MS-MS spectra were acquired at 17,500 fwhm and excluded from
further fragmentation for 30 s.
Raw files were processed as a single batch using the MaxQuant
proteomics software package version 1.5.0.0 [55]. Spectra were
searched using the built-in Andromeda search engine and the
UniProt reference database for human proteins. Cysteine
carbamidomethylation was set as a fixed modification, and methion-
ine oxidation and N-terminal acetylation were selected as variable
modifications. Both peptide and protein false discovery rates (FDRs)
were set to 0.01, the minimum peptide length was set at seven
amino acids, and up to two missed cleavages were tolerated. Some
bioinformatics analysis was performed in the Perseus package
bundled with MaxQuant [56]. Data were filtered by removing
matches to the reverse database, proteins only identified with modi-
fied peptides, and common contaminants and intensity values were
log10 transformed. For label-free experiments, data were uploaded
to the CRAPome.org online analysis tool [25,26]. The default
settings were used for all analysis in CRAPome (FC-A, user, default,
average; FC-B, all, stringent, geometric; SAINT-express, user, aver-
age, virtual controls 10, all replicates). Scores were downloaded and
exported to ProHits-Viz to make dot plots or to Cytoscape for
network diagrams [57,58].
For SILAC experiments, heavy/light ratios were log2 transformed
and outliers were identified using the significance A function
(Benjamini–Hochberg procedure) in Perseus defining a threshold of
0.05. The significance A function was run on each triplicate DWWY,
DRRL and DPIP2 experiment and gene names and SILAC ratios were
compiled and carried forward for subsequent analysis. Principal
component analysis (PCA) was performed in R using the mean
heavy/light ratios of each significant protein and the “prcomp” and
“biplot” functions.
The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE [59] partner repos-
itory with the data set identifier PXD008686.
Expanded View for this article is available online.
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